Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is well known as an aggressive disease with poor survival. This has sparked trials of alternate immune-based therapies in MPM. While up to a quarter of MPM patients respond to immune checkpoint inhibitors (ICIs), predicting response remains challengin...

Descripción completa

Detalles Bibliográficos
Autores principales: Brockwell, Natasha K., Alamgeer, Muhammad, Kumar, Beena, Rivalland, Gareth, John, Thomas, Parker, Belinda S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354134/
https://www.ncbi.nlm.nih.gov/pubmed/32676326
http://dx.doi.org/10.21037/tlcr-19-485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354134/
https://www.ncbi.nlm.nih.gov/pubmed/32676326
http://dx.doi.org/10.21037/tlcr-19-485

Ejemplares similares